Across TCGA pan-cancer cohorts, XRCC3 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of XRCC3’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where XRCC3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types XRCC3 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.
LSCC and COAD are the cancer types where XRCC3 tumor–normal differential expression is most reproducible.